Healthcare
Qiagen N.V.(QGEN)
Live Price
Offline$36.95
+1.01% today
1Y Change
-21.69%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $7.06B
- Revenue Growth
- +5.7%
- EPS Growth
- +423.1%
- Dividend Yield
- 7.4%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Qiagen N.V. (QGEN) is a Healthcare stock with a market cap of $7.06B and listed on NYSE. The stock last traded around $36.95 and down 21.7% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +5.7%, EPS growth of +423.1%, a dividend yield of 7.4%. What stands out right now is revenue +5.7%, EPS +423.1%, free cash flow -10.5% with operating margin 24.9% and ROIC 7.8%. The dividend matters to the case here, with a current yield around 7.4%. Valuation is more restrained than many high-expectation growth names at P/E 16.7 and price/sales 3.4. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines QGEN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+5.7% vs +7.6% peer median
Operating Margin
Above sector median
+24.9% vs +19.4% peer median
P/E
Below sector median
16.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +5.7% and EPS at +423.1%, with operating margin around 24.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 7.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -2.7% | -5.1% | +9.1% |
2026 Feb 4, 2026 | +1.6% | -0.9% | -1.3% | -10.2% |
2025 Nov 4, 2025 | +4.9% | -0.2% | +0.1% | +6.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QGEN
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
QGEN Max Drawdown
-41.38%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QGEN and SPY.
Company Overview
Qiagen N.V.
New York Stock Exchange
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
- Leadership
- Thierry L. Bernard
- IPO Date
- Jun 28, 1996
- Employees
- 5.7k
- Street Address
- Hulsterweg 82
- Mailing
- Venlo, 5912 PL
- Region
- Venlo, NL
- Reporting Currency
- USD
- Investor Line
- 31 77 355 6600
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 16.7
- EV/EBITDA
- 11.0
- Price/Sales
- 3.4
- Price/Book
- 1.9
Growth
- Revenue
- +5.7%
- EPS
- +423.1%
- Free Cash Flow
- -10.5%
Profitability
- Gross Margin
- 61.8%
- Operating Margin
- 24.9%
- Net Margin
- 20.3%
- ROE
- 11.9%
- ROIC
- 7.8%
Balance Sheet
- Debt/Equity
- 0.44
- Current Ratio
- 3.90
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.